Trump Administration Plans Faster FDA Reviews for Smoke-Free Nicotine Products

The Trump administration is preparing to overhaul the U.S. regulatory process for smoke-free nicotine products, potentially creating a faster route to market for vapes and nicotine pouches, according to The Wall Street Journal.

The Food and Drug Administration is expected to announce changes to its premarket review framework in the coming days. The proposed approach would simplify scientific study requirements and reduce review times for non-combustible nicotine products, including flavored vapes and oral nicotine pouches.

Current FDA rules require manufacturers to undergo extensive reviews before selling new tobacco products. Industry participants have complained that the process can take years and involves significant costs. Altria Group’s NJOY vaping business recently joined other companies in suing the FDA over delays in reviewing product applications.

A faster FDA authorization process could benefit major tobacco companies such as Altria Group (NYSE: MO), Philip Morris International (NYSE: PM) and British American Tobacco (NYSE: BTI), which have increasingly invested in smoke-free alternatives as cigarette consumption declines.

Administration officials reportedly see regulatory reform as a way to compete with illicit and unauthorized nicotine products that have gained a significant presence in the U.S. market. Creating clearer legal pathways for alternative nicotine products could help regulators shift consumers toward authorized products while strengthening efforts against non-compliant imports.

The proposal, however, is likely to face resistance from public health organizations and lawmakers concerned about youth nicotine use. Critics argue that approving more flavored vaping products could make nicotine more attractive to younger consumers and say the FDA should focus on enforcement rather than reducing approval requirements.

For tobacco companies and investors, the potential FDA changes could have significant commercial implications. Faster approvals may reduce regulatory costs and allow companies to expand their smoke-free product portfolios more quickly. Philip Morris, Altria and British American Tobacco have all positioned alternative nicotine products as important sources of future growth as the industry continues its transition away from traditional combustible cigarettes.